Press Release Archive
- July 28th, 2008
- OrbusNeich Adds Sapphire™ NC Coronary Dilatation Catheter to Product Line-Up
- July 7th, 2008
- Data Presented at Annual Meeting of Japanese Society of Interventional Cardiology Demonstrate OrbusNeich’s Genous™ Bio-engineered R Stent™ Has Better Outcomes When Compared to Drug-Eluting Stents
- June 9th, 2008
- OrbusNeich Receives CE Mark Approval for Scoreflex™ Coronary Dilatation Catheter
- May 28th, 2008
- OrbusNeich Receives Approval to Market Genous™ Bio-engineered R stent™ in Taiwan
- May 15th, 2008
- Multiple Clinical Data Presentations at EuroPCR 2008 Support Use of OrbusNeich’s Genous™ Bio-engineered R stent™ as Safe Alternative to Drug-Eluting Stents
- May 8th, 2008
- Data from Randomized Pilot Study, Real-World Use of OrbusNeich’s Genous™ Bio-engineered R stent™ to be Presented in Symposium at EuroPCR 2008
- May 1st, 2008
- Clinical Impact of OrbusNeich’s Genous™ Bio-engineered R stent™ is Subject of Symposium at 16th Annual Scientific Congress of Hong Kong College of Cardiology
- April 22nd, 2008
- Symposium at Angioplasty Summit TCT Asia Pacific 2008 Features OrbusNeich’s Genous™ Bio-engineered R stent™
- April 7th, 2008
- OrbusNeich Receives CE Mark Approval for Sapphire™ 1.25mm PTCA Dilatation Catheter
- March 26th, 2008
- Multiple Presentations at ACC.08 Feature OrbusNeich’s Genous™ Bio-engineered R stent™
- February 15th, 2008
- OrbusNeich’s Genous™ Bio-Engineered R Stent™ is Feasible in Acute Myocardial Infarction Patients, American Heart Journal Paper Reports
- November 8th, 2007
- 5,000 Patients Treated With OrbusNeich’s Genous™ Bio-engineered R Stent™ Now Enrolled in Real-Life Use Global Registry
- October 18th, 2007
- OrbusNeich’s Genous™ Bio-Engineered R Stent™ is Subject of Sessions on Innovation at TCT 2007
- September 3rd, 2007
- Data from Patient Subsets of e-HEALING, a Worldwide Registry, Support Use of OrbusNeich\'s Genous™ Bio-engineered R Stent™ as Alternative to Drug- Eluting Stents
- August 30th, 2007
- Dr. Robbert de Winter to Present Pros and Cons of Drug-Eluting Stents and the Benefits of Using an Alternative Pro-Healing Stent to European Cardiologists
- July 30th, 2007
- OrbusNeich Expands Global Sales and Marketing Team
- May 23rd, 2007
- Efficacy of OrbusNeich’s Genous™ Bio-Engineered R Stent Compares Favorably to Drug-Eluting Stents
- May 21st, 2007
- OrbusNeich Receives CE Mark Approval for Blazer™ Cobalt Chromium Stent, Sapphire™ PTCA Dilatation Catheter, Lumina™ Guiding Catheter
- June 23rd, 2006
- Long Term Follow Up With Genous™ Stent Confirms Continuing Vascular Healing; Contrary To Delayed Restenosis With Drug Eluting Stents
- March 1st, 2006
- Healing Stent Nine Month Mace Rate Similar to Drug Eluting Stents
- February 2nd, 2006
- B. Wayne Johnson Promoted to Orbusneich Chief Operating Officer
- November 8th, 2005
- Pro-Healing Coronary Stent Demonstrates Impressive Patient Results
- September 19th, 2005
- OrbusNeich Announces Significant Developments in HEALING Clinical Program with Genous™ Bio-engineered Stent
- September 14th, 2005
- Judith Jaeger Joins OrbusNeich as Director of Clinical Research
- September 5th, 2005
- OrbusNeich Receives 2005 Technology Innovation Award for its Pioneering Bio-engineered Stent Technology
- August 22nd, 2005
- OrbusNeich Receives CE Mark Approval for Genous™ World‘s First Bio-engineered Stent
- February 4th, 2005
- OrbusNeich Appoints Director of Regulatory Programs
- January 26th, 2005
- Neich Medical Acquires Orbus Medical Technologies,
Acquisition is the Outcome of a Long, Synergistic Relationship
